Assessment of Empiric Vancomycin Regimen in the Neonatal Intensive Care Unit

Ruthol Ywaya and Brandi Newby

ABSTRACT

Background: Vancomycin is used to treat serious gram-positive infections in neonates. Currently, there is no consensus on the preferred empiric dosing regimen or target trough vancomycin levels for neonates. The current Fraser Health empiric dosing regimen, implemented in 2010, was designed to achieve target trough levels of 5 to 15 mg/L.

Objectives: To determine the percentage of neonates receiving vancomycin in whom target trough levels of 5 to 15 mg/L were achieved, to identify the times to negative culture result and clinical resolution, and to determine the incidence of nephrotoxicity.

Methods: A chart review was completed for patients who had received vancomycin in the neonatal intensive care unit of either Surrey Memorial Hospital or Royal Columbian Hospital from June 2012 to May 2017 and for whom at least 1 interpretable vancomycin level was available.

Results: A total of 87 vancomycin encounters (in 78 neonates) were identified in which the drug had been given according to the Fraser Health empiric dosing regimen. Target trough vancomycin level (5 to 15 mg/L) was achieved in 75% of these encounters. The mean times to negative culture result and clinical resolution were 5 and 6 days, respectively. There was no statistically significant correlation between vancomycin level and time to clinical resolution ($r_p = 0.366, p = 0.072$). Among cases in which the trough vancomycin level exceeded 15 mg/L, the incidence of nephrotoxicity was 22% (4/18).

Conclusions: The current Fraser Health empiric dosing regimen for vancomycin achieved target trough levels of the drug for most neonates in this study. Targeting trough levels less than 15 mg/L when appropriate to the infection type may limit nephrotoxicity associated with vancomycin in neonates. Further studies are needed to evaluate the clinical significance of various vancomycin levels.

Keywords: neonatal intensive care unit, newborn, vancomycin, pharmacokinetics, clinical effectiveness

Can J Hosp Pharm. 2019;72(3):211-8

RÉSUMÉ

Contexte : La vancomycine est utilisée dans le traitement d’infections graves à bactéries à Gram positif chez le nouveau-né. Il n’y a pour l’instant pas de consensus quant à la posologie empirique ou aux concentrations minimales visées de vancomycine à privilégier chez le nouveau-né. La posologie empirique actuelle de la Fraser Health, instaurée en 2010, visait des concentrations minimales de 5 à 15 mg/L.

Objectifs : Déterminer le pourcentage de nouveau-nés ayant reçu les concentrations minimales visées de 5 à 15 mg/L de vancomycine, établir le temps nécessaire à l’obtention d’un résultat de culture négatif et celui nécessaire à la disparition clinique des symptômes et déterminer l’incidence de la néphrotoxicité.

Méthodes : Les investigateurs ont analysé des dossiers de patients ayant reçu de la vancomycine pendant leur séjour à l’unité de soins intensifs néonatals du Surrey Memorial Hospital ou du Royal Columbian Hospital entre juin 2012 et mai 2017, qui mentionnaient au moins une concentration de vancomycine interprétable.

Résultats : Ils ont répertorié 87 traitements de vancomycine (chez 78 nouveau-nés) administrés selon la posologie empirique de la Fraser Health. Les concentrations minimales visées de 5 à 15 mg/L ont été atteintes dans 75% de ces traitements. Le temps moyen nécessaire à l’obtention d’un résultat de culture négatif ou à la disparition clinique des symptômes était respectivement de cinq et de six jours. Aucune corrélation statistiquement significative entre les concentrations de vancomycine et le temps nécessaire à la disparition clinique des symptômes n’a été relevée ($r_p = 0.366, p = 0.072$). Parmi les cas où les concentrations minimales de vancomycine dépassaient 15 mg/L, l’incidence de néphrotoxicité était de 22% (4/18).

Conclusions : La posologie empirique de vancomycine actuellement en place à la Fraser Health a permis d’atteindre les concentrations minimales visées de médicament pour la plupart des nouveau-nés de la présente étude. Cibler des concentrations minimales de moins de 15 mg/L lorsque cela est pertinent en fonction du type d’infection pourrait limiter le nombre de cas de néphrotoxicité associés à la vancomycine chez les nouveau-nés. De plus amples études sont nécessaires pour évaluer la portée clinique de différentes concentrations de vancomycine.

Mots clés : unité de soins intensifs néonatals, nouveau-né, vancomycine, pharmacocinétique, efficacité clinique
INTRODUCTION

In the neonatal intensive care unit (NICU), vancomycin is used to treat serious gram-positive infections such as sepsis, meningitis, pneumonia, skin and soft-tissue infections, necrotizing enterocolitis, and osteomyelitis. The predominant gram-positive organisms of late-onset infections in the NICU are coagulase-negative *Staphylococcus* and *Staphylococcus aureus*.1,2 These organisms have been shown to be sensitive to vancomycin when the minimum inhibitory concentration (MIC) is 2 mg/L or less.3

Time above the MIC or area under the curve to MIC has been used to assess vancomycin efficacy in adults, but there is lack of evidence for use of these measures in neonates. Vancomycin has been shown to exert bactericidal activity against *Staphylococcus* when the unbound levels are 4 to 5 times the MIC.4,5 Because vancomycin is about 50% protein-bound, this translates to target levels of 4 to 5 mg/L for MIC of 0.5 mg/L, 8 to 10 mg/L for MIC of 1 mg/L, and 15 to 20 mg/L for MIC of 2 mg/L.

Other factors, including the type, location, and severity of infection, should also be considered when determining the target vancomycin level. For patients with infections at sites that are difficult to penetrate, such as the lungs or brain, adult guidelines suggest targeting higher serum levels, specifically 15 to 20 mg/L, regardless of MIC, to ensure adequate penetration of the vancomycin.6,8 However, for less serious infections, such as uncomplicated infections of skin or soft tissue or infections of the urinary tract, lower targets may be adequate because of excellent clinical response rates with traditional vancomycin dosing.8

Pharmacokinetic data show that trough levels of 5 to 10 mg/L are sufficient to resolve infections with coagulase-negative *Staphylococcus* in neonates. By contrast, in adults, higher trough levels (10 to 20 mg/L) are associated with increased efficacy relative to lower trough levels (<10 mg/L), particularly in patients with methicillin-resistant *Staphylococcus aureus*.6,9,10 However, in vitro studies have shown no difference in efficacy with concentrations above the MIC.11 In addition, prolonged exposure to serum levels close to the MIC has been associated with increased risk of resistance.12

Currently, there is no consensus in the literature regarding the optimal vancomycin dosing regimen or target trough concentrations that are associated with better clinical outcomes in neonates. Some organizations have adopted the target levels for adults without evaluating the potential need for higher targets or the risks associated with these adult targets in the neonatal population. It is also not clear whether the recommended adult target levels are required to achieve desired clinical outcomes in neonates. A study by Barriere and others13 suggested that higher vancomycin trough levels do not improve the clinical response but likely increase the incidence of nephrotoxicity. Relative to adults, neonates have a larger extracellular fluid volume, which could influence the distribution of vancomycin. Additionally, neonates have lower renal elimination and protein binding than adults, and vancomycin efficacy may be influenced by these pharmacokinetic differences.10

Following a local neonatal review in 2002 (unpublished data), the Fraser Health empiric vancomycin regimen was changed at one site in the health authority, and the revised neonatal regimen was then implemented regionally in 2010 (Table 1). This regimen was designed to generate trough levels of 5 to 15 mg/L for the majority of NICU patients. The current study was undertaken to evaluate the empiric regimen that had been in effect since 2010, to determine the percentage of neonates in whom target trough vancomycin levels of 5 to 15 mg/L were achieved, to identify the times to negative culture result and clinical resolution, and to determine the incidence of nephrotoxicity.

**METHODS**

Ethics approval for this study was obtained from the Fraser Health Research Ethics Board.

For this chart review, the pharmacy department of Surrey Memorial Hospital generated a list of neonates who received vancomycin in the NICU of either Surrey Memorial Hospital or the Royal Columbian Hospital between June 1, 2012, and May 31, 2017. Any neonate on this list for whom an interpretable vancomycin level was available and whose electronic chart was accessible was included in the study. An interpretable vancomycin

<table>
<thead>
<tr>
<th>Postmenstrual Age</th>
<th>Vancomycin Dosage</th>
<th>No. of Patient Encounters by Dose (n = 87)</th>
<th>Mean Vancomycin Level (Range) (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 30 weeks</td>
<td>10 mg/kg IV q12h</td>
<td>10 mg/kg; n = 42</td>
<td>11.0 (ND to 18.1)</td>
</tr>
<tr>
<td>≥ 30 weeks, 0–7 days of life</td>
<td>10–15 mg/kg IV q12h</td>
<td>10 mg/kg; n = 1, 11 mg/kg; n = 1, 15 mg/kg; n = 3</td>
<td>11.9 (NA), 12.2 (NA), 16.2 (8.5 to 29.5)</td>
</tr>
<tr>
<td>≥ 30 weeks, &gt;7 days of life</td>
<td>10–15 mg/kg IV q8h</td>
<td>10 mg/kg; n = 18, 11 mg/kg; n = 4, 12 mg/kg; n = 3, 13 mg/kg; n = 7, 14 mg/kg; n = 3, 15 mg/kg; n = 5</td>
<td>11.2 (ND to 21.3), 11.9 (10.2 to 15.4), 9.9 (7.5 to 12.3), 14.9 (8.6 to 21.2), 13.6 (10.1 to 19.1), 12.3 (7.4 to 17.4)</td>
</tr>
</tbody>
</table>

NA = not applicable, ND = not detectable.
level was defined by a serum sample for measurement of trough level drawn within 60 min before the third dose (or a later dose); alternatively, if 2 measurements had been done for a given patient, the serum trough level could be calculated from the 2 results, as described below. Patients were excluded if the postmenstrual age was greater than 45 weeks, if there was no electronic chart, if no vancomycin level had been recorded, or if vancomycin measurements had been inappropriately obtained.

For this study, the data collected included the following information about the patient: gestational age, birth weight, postmenstrual age, day of life and weight when vancomycin was started, baseline feeding status, urine output, concurrent vasopressor use, concurrent antibiotic use as well as antibiotic use within 48 h before initiation of vancomycin therapy, and infection type. In cases with a positive culture result, the MIC of the infective organism was recorded, if available. The vancomycin regimen, duration of therapy, and serum levels of vancomycin were also recorded. For patients who had received more than 1 course of vancomycin, all courses within the study period were included in the analysis, entered as separate encounters. For patients with multiple samples drawn during a single vancomycin course, only the first measured level obtained with the empiric regimen was assessed.

In cases where a serum trough level within 60 min of next dose was not available, but 2 interpretable levels had been obtained, pharmacokinetic calculations were used. The individual elimination rate constant (K) and extrapolated trough level were calculated according to the 2-point modified Sawchuk–Zaske method.14

Time to negative culture result was determined by analyzing data for patients with an initial positive culture result and then a subsequent repeat culture result; this analysis included only patients with an indication that required vancomycin therapy. Repeat culture was performed at the discretion of the attending physician. Results from repeat culture of endotracheal tube samples were excluded because of possible colonization. The time to negative culture result was defined as the number of days between initiation of vancomycin and the first negative result.

For clinical outcomes, the following information was collected: need for and type of respiratory support; oxygen requirements; recorded instances of apnea, bradycardia, or desaturation; vasopressor use; temperature of patient and isolate; feeding volume; any medical imaging reports; and complete blood counts. Baseline data were collected for the patients for the day before initiation of vancomycin for comparison with data collected throughout the vancomycin course. Clinical resolution was defined as a return to baseline clinical status. For determining whether patients had experienced nephrotoxicity, the following data were collected: serum creatinine, urine output, and concomitant nephrotoxic medications. Neonatal nephrotoxicity was defined on the basis of either of the following criteria: increase in serum creatinine of at least 26.5 μmol/L or at least 50%.15

Descriptive statistics were used to analyze the data in this study. The Spearman rho correlation coefficient was calculated to describe the relation between vancomycin level and time to clinical resolution. For this 2-sided test, p < 0.05 was deemed to represent statistical significance.

RESULTS

In total, 147 NICU patients received vancomycin during the study period (Figure 1), of whom 78 were included in the analysis and 69 were excluded. Several of the patients received more than 1 course of vancomycin therapy; as such, there were 87 encounters in which neonates received vancomycin according to the Fraser Health empiric regimen.

For the 87 patient encounters, the mean postmenstrual age was 30 weeks when vancomycin was started (Table 2). The most common infections that required vancomycin were coagulase-negative Staphylococcus bacteremia or sepsis (22 [25%]), suspected sepsis (23 [26%]), and necrotizing enterocolitis (19 [22%]). There were no cases of methicillin-resistant Staphylococcus aureus. For 29 cultures, the MIC was reported. Of these, 6 (21%) had MIC less than or equal to 0.5 mg/L, 16 (55%) had MIC of 1 mg/L, 7 (24%) had MIC of 2 mg/L, and none had MIC above 2 mg/L.

Among the 87 encounters, 43 involved an empiric vancomycin dosage of 10 mg/kg IV q12h, 1 involved a dosage of 11 mg/kg IV q12h, 3 involved a dosage of 15 mg/kg IV q12h, 18 involved a dosage of 10 mg/kg IV q8h, 5 involved a dosage of 15 mg/kg IV q8h, and 17 involved a dosage range of 11 to 14 mg/kg IV q8h (Table 1). The average duration of vancomycin therapy was 7 days. We did not evaluate the reasons why patients required prolonged courses of therapy, because all patients in this study had received antibiotics for the recommended duration for the presumed diagnoses.

Data for vancomycin levels were interpretable for all but 1 of the 87 patient encounters; for the sole exception, the pharmacokinetic calculation was performed. With the Fraser Health empiric regimen, 65 (75%) of the 87 vancomycin trough levels were within the target range (5 to 15 mg/L), and 14 (16%) were between 15.1 and 20 mg/L, for a total of 79 (91%) between 5 and 20 mg/L (Figure 2); 48 (55%) of the 87 measured trough levels were between 10 and 20 mg/L.

A positive culture result was obtained for 36 (41%) of the 87 encounters (Figure 3). For determination of time to negative culture result, 21 encounters were included. The other 15 encounters with an initially positive culture result were excluded for the following reasons: endotracheal tube sample (n = 5), no indication for vancomycin (n = 4), and no repeat culture performed (n = 6). The mean time to repeat culture and the time to negative culture result were 4 and 5 days, respectively (range 1 to 12 days for both). For 7 of the 21 encounters with repeat culture, the repeat result was positive; for all of these, negative results were eventually obtained on subsequent repeat culture.
For determination of clinical resolution, 4 encounters were excluded because there was no indication for vancomycin. No change from baseline clinical status was documented for 58 (70%) of the 83 vancomycin encounters included in this analysis. The other 25 encounters (30%) had a change from baseline clinical status followed by an eventual return to baseline status, with time to clinical resolution of about 6 days (range 2 to 17 days). For these 25 patients with a change in clinical status from baseline, there was no statistically significant correlation between vancomycin trough level and time to clinical resolution ($r = 0.366, p = 0.072$) (Figure 4).

There were a total of 26 encounters in which concurrent nephrotoxic medications were administered, specifically indomethacin, gentamicin, or furosemide. For 17 of these encounters, the vancomycin level was less than 15 mg/L. Neonatal nephrotoxicity occurred in 4 (5%) of the 78 patients included in this study. The mean time to nephrotoxicity from initiation of vancomycin was 3 days (range 1 to 5 days) (Table 3). For 3 of the 4 patients with nephrotoxicity, gentamicin was the only concomitant nephrotoxic medication administered. One of the patients receiving gentamicin also experienced septic shock requiring vasopressors. The incidence of nephrotoxicity was 22% (4/18) among patients with vancomycin level above 15 mg/L; none of the 60 patients with vancomycin level of 15 mg/L or below experienced nephrotoxicity.

**DISCUSSION**

In this study, the current Fraser Health empiric vancomycin regimen led to vancomycin trough levels between 5 and 15 mg/L, for 75% of patient encounters, with 91% of encounters having trough levels that fell between 5 and 20 mg/L. Given the broad range of neonates (postmenstrual age 24 to 42 weeks) included in this study and the anticipated interpatient variability, the empiric regimen generated acceptable vancomycin trough levels

**Table 2. Patient Characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean (Range) or No. (%) of Encounters*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postmenstrual age (weeks)</td>
<td>30 (24-42)</td>
</tr>
<tr>
<td>Days of life</td>
<td>17 (1-68)</td>
</tr>
<tr>
<td>Birth weight (kg)</td>
<td>1 (0.38-4.25)</td>
</tr>
<tr>
<td>Weight at initiation of vancomycin (kg)</td>
<td>1.2 (0.44-4.25)</td>
</tr>
<tr>
<td>Urine output at initiation of vancomycin (mL/kg per hour)</td>
<td>3 (1.5 to 6.2)</td>
</tr>
<tr>
<td>NPO status</td>
<td>16 (18)</td>
</tr>
<tr>
<td>Vasopressor therapy</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Received antibiotics 48 h prior</td>
<td>38 (44)</td>
</tr>
<tr>
<td>Infections</td>
<td></td>
</tr>
<tr>
<td>CONS bacteremia/sepsis</td>
<td>22 (25)</td>
</tr>
<tr>
<td>Suspected sepsis</td>
<td>23 (26)</td>
</tr>
<tr>
<td>Necrotizing enterocolitis</td>
<td>19 (22)</td>
</tr>
<tr>
<td>Ventilator-associated pneumonia</td>
<td>13 (15)</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>6 (7)</td>
</tr>
<tr>
<td>Other bacteremia (MSSA, Bacillus cereus, group B Streptococcus)</td>
<td>4 (5)</td>
</tr>
</tbody>
</table>

CONS = coagulate-negative Staphylococcus, MSSA = methicillin-sensitive Staphylococcus aureus, NPO = nothing by mouth.

*Mean values are based on 78 unique patients, some of whom had more than 1 course of therapy. Data for number (%) of encounters are based on a denominator of 87 encounters, with each encounter representing an individual course of vancomycin therapy.
**Figure 2.** Scatter plot of vancomycin levels with current empiric regimen. For 2 patients, the vancomycin level was undetectable and data are therefore not shown in the scatter plot.

**Figure 3.** Culture results and clinical status. *All samples with repeat culture (following positive results on initial testing) were negative on subsequent culture.*
for a high percentage of encounters. Ringenberg and others\textsuperscript{16} found that 25.1% of NICU patients achieved serum trough levels between 10 and 20 mg/L with a commonly used empiric vancomycin regimen given in \textit{Neofax: A Manual of Drugs Used in Neonatal Care.}\textsuperscript{17} Dersch-Mills and others\textsuperscript{18} evaluated a different empiric vancomycin regimen and found that only 34% of patients achieved a trough level between 10 to 20 mg/L. In the study reported here, which used a simplified version of the \textit{Neofax} regimen, 55% of trough levels fell between 10 and 20 mg/L.

The target trough vancomycin levels associated with efficacy are not known for neonates. Determination of the target trough level should take into consideration the MIC of the organism being treated and the location and severity of the infection.\textsuperscript{45} In the current study, most of the patients with a positive culture result had organisms with MIC of 1 mg/L or less for vancomycin. Because most of the infections were bacteremia or sepsis-related, a trough level of 8 to 10 mg/L would be appropriate for the majority of these patients. The current empiric vancomycin regimen yielded acceptable trough levels for most of the patients. Therefore, for patients with organisms for which MIC is known, target vancomycin levels could be selected accordingly.

This study also evaluated the clinical significance of vancomycin levels in neonates, a topic that has not been addressed in previous studies. However, a limitation of this study was that the information about clinical status was collected retrospectively, and only 25 (30%) of patient encounters had a documented change from baseline clinical status after initiation of vancomycin. The mean time to clinical resolution for these 25 patients was 6 days (range 2 to 17). Various studies have shown time to clinical resolution of 3 to 7 days in adults with community-acquired pneumonia.\textsuperscript{19-22} A study involving adults with sepsis and concurrent bacteremia showed a median time to clinical response of 2 or 4 days, depending on the type of blood culture identification test.\textsuperscript{23} Clinical resolution in the neonatal population may be delayed because the source of infection is not always removed once the infection has been diagnosed. For example, central lines or

---

**Table 3. Characteristics of Patients with Nephrotoxicity (n = 4)**

<table>
<thead>
<tr>
<th>PMA (weeks)</th>
<th>Day of Life when Vancomycin Started</th>
<th>Day of Life when Nephrotoxicity Documented</th>
<th>Urine Output* (mL/kg/h)</th>
<th>SCr (µmol/L)</th>
<th>Increase in SCr</th>
<th>Vancomycin Level (mg/L)</th>
<th>Concomitant Nephrotoxins</th>
</tr>
</thead>
<tbody>
<tr>
<td>25+1</td>
<td>10</td>
<td>15</td>
<td>2.9</td>
<td>74 → 130</td>
<td>76%</td>
<td>13.6 → 22.4</td>
<td>Yes</td>
</tr>
<tr>
<td>27+4</td>
<td>13</td>
<td>14</td>
<td>2.2</td>
<td>74 → 126</td>
<td>70%</td>
<td>18.1</td>
<td>Yes</td>
</tr>
<tr>
<td>28+4</td>
<td>3</td>
<td>7</td>
<td>0.58</td>
<td>40 → 68</td>
<td>70%</td>
<td>15.3</td>
<td>No</td>
</tr>
<tr>
<td>34+11</td>
<td>1</td>
<td>4</td>
<td>0</td>
<td>107 → 168</td>
<td>57%</td>
<td>21</td>
<td>Yes</td>
</tr>
</tbody>
</table>

PMA = postmenstrual age, SCr = serum creatinine.

*Lowest documented urine output during treatment.
+Patient had septic shock requiring vasopressors.
endotracheal tubes are often not removed until the patient has become clinically stable and can tolerate the necessary changes. No statistically significant correlation between vancomycin trough level and clinical resolution was found in this study. This finding may have been confounded by the small sample size, but it raises questions as to whether an increase in vancomycin levels increases efficacy and whether lower targets would be sufficient to achieve clinical resolution, while minimizing the risk of toxicity. With regard to microbiological cure, the collection of samples for repeat culture was at the discretion of the physician at the time of care; as such, the actual time to microbiological cure was not known and might have been earlier than what was found in this review, which would have been apparent only if culture samples had been collected earlier.

Lestner and others24 reported that the incidence of vancomycin nephrotoxicity in neonates was 1% to 9%, similar to the overall incidence of nephrotoxicity in our study (5%). A review by Bhargava and others25 evaluated the risk of acute kidney injury in NICU patients in relation to serum trough concentrations and showed that trough concentrations above 15 mg/L were associated with increased incidence of nephrotoxicity (18.2%) relative to trough concentrations between 10 and 15 mg/L (0%) and less than 10 mg/L (1.4%). The current study had similar findings, in that the incidence of neonatal nephrotoxicity was higher with vancomycin trough levels above 15 mg/L (22%) relative to levels of 15 mg/L or less (0%). However, it was difficult to determine whether the nephrotoxicity was a result of the vancomycin or other risk factors, including infection-related factors or concomitant nephrotoxins. Among the 4 patients with nephrotoxicity, the only additional risk factors identified were the use of concurrent gentamicin (for 3 patients) and septic shock requiring vasopressors (for 1 patient). Therefore, if trough vancomycin levels above 15 mg/L are targeted, it may be prudent to observe patients closely for signs and symptoms of nephrotoxicity and to assess, on a case-by-case basis, whether levels above 15 mg/L are truly needed.

Little appears to be known about the incidence of vancomycin-induced ototoxicity in neonates. Vancomycin-induced ototoxicity has not been consistently shown in animal studies, and clinical studies suggest that apparent vancomycin-induced ototoxicity may in fact be related to administration of impure fermented products and concomitant ototoxins.26 We did not evaluate vancomycin-induced ototoxicity in this study because of its rare occurrence and inconsistent results in the available literature.

CONCLUSION

The current Fraser Health empiric vancomycin regimen generated trough levels within the target range of 5 to 15 mg/L for most patients in this study. All of the patients received vancomycin for the treatment duration appropriate for their diagnosis, and the mean times to microbiological and clinical resolution were 5 and 6 days, respectively. Of concern was the fact that 22% of patients with vancomycin trough levels above 15 mg/L experienced nephrotoxicity. Additional studies evaluating the clinical significance of vancomycin levels in neonates are needed to help identify the preferred vancomycin target levels for this patient population and thereby to ensure efficacy and minimize toxicity.

References

Ruthdel Ywowa, BSc(Pharm), ACPR, was, at the time of this study, a Pharmacy Resident with Lower Mainland Pharmacy Services.

Brandi Newby, BSc(Pharm), ACPR, is Coordinator with the Neonatal and Pediatric Pharmacy of Surrey Memorial Hospital, Surrey, British Columbia.

Competing interests: None declared.

Address correspondence to:
Brandi Newby
Surrey Memorial Hospital
Critical Care Tower, Room 2-602
13750 96th Avenue
Surrey BC V3W 1Z2
e-mail: brandi.newby@fraserhealth.ca
Funding: None received.

ON THE FRONT COVER

Mont-Tremblant, Quebec

This photograph of the Mont-Tremblant Ski Resort was taken from the pier on Lac Tremblant in August 2018. Helena Trubuls was enjoying a scenic drive during her summer holiday and used an iPhone 8s to capture the scene. Helena retired from her position as Director of Pharmacy with Halton Healthcare Services earlier this year.

The CJHP would be pleased to consider photographs featuring Canadian scenery taken by CJHP members for use on the front cover of the Journal. If you would like to submit a photograph, please send an electronic copy (minimum resolution 300 dpi) to publications@cshp.pharmacy.